Intersect ENT, Inc. (XENT)
Price:
28.24 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Abiomed, Inc.
VALUE SCORE:
0
2nd position
UFP Technologies, Inc.
VALUE SCORE:
10
The best
Viemed Healthcare, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
NEWS
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
zacks.com
2022-05-10 12:48:16Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.
Orthofix Announces Appointment of Thomas A. West to Board of Directors
businesswire.com
2021-12-14 07:00:00LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix names Thomas A. West to the Company's Board of Directors and appoints him to the Compensation and Talent Development Committee.
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
zacks.com
2021-12-02 13:04:48Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
zacks.com
2021-11-18 12:14:16Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
zacks.com
2021-09-30 11:08:41MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
prnewswire.com
2021-09-13 15:23:00NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Intersect ENT, Inc. ("XENT" or the "Company") (XENT) relating to its proposed acquisition by Medtronic plc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
prnewswire.com
2021-08-09 14:47:00NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25 for each share of Intersect ENT stock that they hold.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
zacks.com
2021-08-09 12:23:15Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
pulse2.com
2021-08-07 22:39:46Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion. The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion appeared first on Pulse 2.0.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
prnewswire.com
2021-08-06 16:31:00NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT) in connection with the proposed acquisition of the Company by Medtronic plc ("Medtronic") (NYSE:MDT). Under the terms of the merger agreement, the Company's shareholders will receive $28.25 per share in cash for each share of Intersect common stock that they hold.
Why Intersect ENT Shot 12% Higher on Friday
fool.com
2021-08-06 16:22:10It's official: A big peer is buying out the specialty medical device maker.
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
businesswire.com
2021-08-06 12:45:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Intersect ENT, Inc. (NASDAQ: XENT) to Medtronic plc for $28.25 per share is fair to Intersect ENT shareholders. Halper Sadeh encourages Intersect ENT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Inters
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
prnewswire.com
2021-08-06 12:12:00MILWAUKEE, Aug. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating Intersect ENT (NASDAQ: XENT) for possible breaches of fiduciary duty and other violations of law in its transaction with Medtronic. Click here to learn how to join the action: https://www.ademilaw.com/case/intersect-ent-inc or call Guri Ademi toll-free at 866-264-3995.
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2021-08-06 09:59:38Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
benzinga.com
2021-08-06 08:19:30Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures.
Intersect ENT Reports Second Quarter 2021 Financial Results
businesswire.com
2021-08-06 07:15:00MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million i
No data to display
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
zacks.com
2022-05-10 12:48:16Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.
Orthofix Announces Appointment of Thomas A. West to Board of Directors
businesswire.com
2021-12-14 07:00:00LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix names Thomas A. West to the Company's Board of Directors and appoints him to the Compensation and Talent Development Committee.
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
zacks.com
2021-12-02 13:04:48Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
zacks.com
2021-11-18 12:14:16Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
zacks.com
2021-09-30 11:08:41MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
prnewswire.com
2021-09-13 15:23:00NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Intersect ENT, Inc. ("XENT" or the "Company") (XENT) relating to its proposed acquisition by Medtronic plc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
prnewswire.com
2021-08-09 14:47:00NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25 for each share of Intersect ENT stock that they hold.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
zacks.com
2021-08-09 12:23:15Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
pulse2.com
2021-08-07 22:39:46Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion. The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion appeared first on Pulse 2.0.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
prnewswire.com
2021-08-06 16:31:00NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT) in connection with the proposed acquisition of the Company by Medtronic plc ("Medtronic") (NYSE:MDT). Under the terms of the merger agreement, the Company's shareholders will receive $28.25 per share in cash for each share of Intersect common stock that they hold.
Why Intersect ENT Shot 12% Higher on Friday
fool.com
2021-08-06 16:22:10It's official: A big peer is buying out the specialty medical device maker.
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
businesswire.com
2021-08-06 12:45:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Intersect ENT, Inc. (NASDAQ: XENT) to Medtronic plc for $28.25 per share is fair to Intersect ENT shareholders. Halper Sadeh encourages Intersect ENT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Inters
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
prnewswire.com
2021-08-06 12:12:00MILWAUKEE, Aug. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating Intersect ENT (NASDAQ: XENT) for possible breaches of fiduciary duty and other violations of law in its transaction with Medtronic. Click here to learn how to join the action: https://www.ademilaw.com/case/intersect-ent-inc or call Guri Ademi toll-free at 866-264-3995.
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2021-08-06 09:59:38Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
benzinga.com
2021-08-06 08:19:30Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures.
Intersect ENT Reports Second Quarter 2021 Financial Results
businesswire.com
2021-08-06 07:15:00MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million i